Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $8.45 USD
Change Today -0.79 / -8.55%
Volume 899.1K
RGLS On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 8:10 PM 09/3/15 All times are local (Market data is delayed by at least 15 minutes).

regulus therapeutics inc (RGLS) Snapshot

Open
$9.19
Previous Close
$9.24
Day High
$9.35
Day Low
$8.41
52 Week High
11/10/14 - $25.60
52 Week Low
10/13/14 - $6.23
Market Cap
438.7M
Average Volume 10 Days
872.7K
EPS TTM
$-1.23
Shares Outstanding
51.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for REGULUS THERAPEUTICS INC (RGLS)

regulus therapeutics inc (RGLS) Related Businessweek News

View More BusinessWeek News

regulus therapeutics inc (RGLS) Details

Regulus Therapeutics Inc., a biopharmaceutical company, focuses on the discovery and development of drugs that target microRNAs for the treatment of various diseases in the United States. It uses its microRNA product platform to develop anti-miRs, which are chemically modified and single-stranded oligonucleotides. The company’s clinical stage products include RG-101, which is a GalNAc-conjugated anti-miR that targets microRNA-122 for the treatment of patients with chronic hepatitis C virus infection; and RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome, a life-threatening kidney disease. It has strategic collaborations with Biogen Idec MA Inc. for the evaluation of the use of microRNA signatures as a biomarker for human patients with multiple sclerosis; AstraZeneca AB to discover and develop microRNA therapeutics for cardiovascular diseases, metabolic diseases, and oncology; and GSK to discover and develop microRNA therapeutics for immuno-inflammatory diseases. The company also has strategic collaboration with Sanofi for the discovery and development of microRNA therapeutics comprising miR-21 preclinical fibrosis program for the treatment of Alport syndrome and preclinical program for oncology indications; and preclinical programs targeting miR-221/222 for oncology indications. Regulus Therapeutics Inc. was founded in 2007 and is headquartered in San Diego, California.

85 Employees
Last Reported Date: 08/5/15
Founded in 2007

regulus therapeutics inc (RGLS) Top Compensated Officers

Principal Financial & Accounting Officer, Chi...
Total Annual Compensation: $244.7K
Compensation as of Fiscal Year 2014.

regulus therapeutics inc (RGLS) Key Developments

Regulus Therapeutics Inc. Appoints Michael Huang, M.D. as Vice President, Clinical Development

Regulus Therapeutics Inc. announced the appointment of Michael Huang, M.D. as Vice President, Clinical Development. Dr. Huang is an experienced drug developer with proven success in advancing programs through clinical trials that led to commercialization in a wide range of therapeutic areas. At Regulus, Dr. Huang will be responsible for leading the company's global clinical operations and medical affairs and will serve as a key member of the executive leadership team. Most recently, Dr. Huang served as Vice President, Clinical Development of Auspex Pharmaceuticals Inc. (acquired by Teva Pharmaceutical Industries Ltd. in May 2015) and was responsible for providing project and clinical leadership across multiple programs focused on the treatment of central nervous system disorders. Prior to Auspex, Dr. Huang served in medical leadership roles at Santarus Inc., Spectrum Pharmaceuticals Inc., Phenomix Corporation and Valeant Pharmaceuticals International.

Regulus Therapeutics Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Regulus Therapeutics Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company announced revenues under strategic alliances of $3,834,000 compared to $736,000 for the same period a year ago. Loss from operations was $21,181,000 compared to $13,013,000 for the same period a year ago. Loss before income taxes was $21,037,000 compared to $11,973,000 for the same period a year ago. Net loss was $21,035,000 or $0.41 per basic and diluted share compared to $11,973,000 or $0.29 per diluted share for the same period a year ago. The increase in revenue was due to the overall advancement in work with strategic alliance partners and collaborators. For the six months, the company announced revenues under strategic alliances of $8,034,000 compared to $2,367,000 for the same period a year ago. Loss from operations was $34,052,000 compared to $23,718,000 for the same period a year ago. Loss before income taxes was $35,528,000 compared to $24,713,000 for the same period a year ago. Net loss was $35,522,000 or $0.70 per basic and diluted share compared to $24,714,000 or $0.57 per basic and diluted share for the same period a year ago.

Regulus Therapeutics Inc. to Report Q2, 2015 Results on Aug 04, 2015

Regulus Therapeutics Inc. announced that they will report Q2, 2015 results at 5:00 PM, Eastern Daylight on Aug 04, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RGLS:US $8.45 USD -0.79

RGLS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Arbutus Biopharma Corp $6.93 USD -0.06
Benitec Biopharma Ltd A$0.51 AUD -0.015
Dicerna Pharmaceuticals Inc $10.63 USD -0.71
Galena Biopharma Inc $1.62 USD 0.00
Silence Therapeutics PLC 260.00 GBp 0.00
View Industry Companies
 

Industry Analysis

RGLS

Industry Average

Valuation RGLS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 35.4x
Price/Book 3.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 25.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REGULUS THERAPEUTICS INC, please visit www.regulusrx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.